ACADIA Pharmaceuticals Inc
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog … Read more
ACADIA Pharmaceuticals Inc (ACAD) - Net Assets
Latest net assets as of December 2025: $1.23 Billion USD
Based on the latest financial reports, ACADIA Pharmaceuticals Inc (ACAD) has net assets worth $1.23 Billion USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.56 Billion) and total liabilities ($336.81 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.23 Billion |
| % of Total Assets | 78.47% |
| Annual Growth Rate | N/A |
| 5-Year Change | 126.92% |
| 10-Year Change | 136.76% |
| Growth Volatility | 109.12 |
ACADIA Pharmaceuticals Inc - Net Assets Trend (2000–2025)
This chart illustrates how ACADIA Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for ACADIA Pharmaceuticals Inc (2000–2025)
The table below shows the annual net assets of ACADIA Pharmaceuticals Inc from 2000 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $1.23 Billion | +67.49% |
| 2024-12-31 | $732.79 Million | +69.72% |
| 2023-12-31 | $431.75 Million | +7.83% |
| 2022-12-31 | $400.41 Million | -25.97% |
| 2021-12-31 | $540.89 Million | -13.73% |
| 2020-12-31 | $627.01 Million | -10.32% |
| 2019-12-31 | $699.13 Million | +45.93% |
| 2018-12-31 | $479.08 Million | +42.89% |
| 2017-12-31 | $335.29 Million | -35.32% |
| 2016-12-31 | $518.41 Million | +159.51% |
| 2015-12-31 | $199.76 Million | -35.45% |
| 2014-12-31 | $309.49 Million | +69.93% |
| 2013-12-31 | $182.13 Million | +114.31% |
| 2012-12-31 | $84.98 Million | +263.77% |
| 2011-12-31 | $23.36 Million | -21.31% |
| 2010-12-31 | $29.69 Million | +145.07% |
| 2009-12-31 | $12.11 Million | -77.14% |
| 2008-12-31 | $52.99 Million | -53.49% |
| 2007-12-31 | $113.93 Million | +69.65% |
| 2006-12-31 | $67.16 Million | +70.58% |
| 2005-12-31 | $39.37 Million | +28.33% |
| 2004-12-31 | $30.68 Million | +158.25% |
| 2003-12-31 | $-52.67 Million | -31.38% |
| 2002-12-31 | $-40.09 Million | -324.44% |
| 2001-12-31 | $17.86 Million | +179.36% |
| 2000-12-31 | $-22.51 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to ACADIA Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 181338600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $16.00K | 0.00% |
| Other Comprehensive Income | $1.45 Million | 0.12% |
| Other Components | $3.04 Billion | 247.62% |
| Total Equity | $1.23 Billion | 100.00% |
ACADIA Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of ACADIA Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
CarGurus
NASDAQ:CARG
|
$2.65 Billion |
|
Vista Energy S.A.B. de C.V.
BA:VIST
|
$2.65 Billion |
|
Cinemark Holdings Inc
NYSE:CNK
|
$2.65 Billion |
|
Mianyang Fulin Precision Machining Co Ltd
SHE:300432
|
$2.65 Billion |
|
DiaSorin S.p.A
PINK:DSRLF
|
$2.65 Billion |
|
Sasol Limited
PINK:SASOF
|
$2.65 Billion |
|
Munters Group AB
ST:MTRS
|
$2.64 Billion |
|
Two Harbors Investment Corp.
NYSE:TWOD
|
$2.64 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ACADIA Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 732,793,000 to 1,227,390,000, a change of 494,597,000 (67.5%).
- Net income of 391,000,000 contributed positively to equity growth.
- New share issuances of 49,883,000 increased equity.
- Other comprehensive income increased equity by 1,153,000.
- Other factors increased equity by 52,561,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $391.00 Million | +31.86% |
| Share Issuances | $49.88 Million | +4.06% |
| Other Comprehensive Income | $1.15 Million | +0.09% |
| Other Changes | $52.56 Million | +4.28% |
| Total Change | $- | 67.49% |
Book Value vs Market Value Analysis
This analysis compares ACADIA Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.92x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2000-12-31 | $-21.04 | $20.90 | x |
| 2001-12-31 | $14.79 | $20.90 | x |
| 2002-12-31 | $-27.61 | $20.90 | x |
| 2003-12-31 | $-4.63 | $20.90 | x |
| 2004-12-31 | $2.96 | $20.90 | x |
| 2005-12-31 | $1.79 | $20.90 | x |
| 2006-12-31 | $2.41 | $20.90 | x |
| 2007-12-31 | $3.24 | $20.90 | x |
| 2008-12-31 | $1.43 | $20.90 | x |
| 2009-12-31 | $0.32 | $20.90 | x |
| 2010-12-31 | $0.77 | $20.90 | x |
| 2011-12-31 | $0.45 | $20.90 | x |
| 2012-12-31 | $1.54 | $20.90 | x |
| 2013-12-31 | $2.12 | $20.90 | x |
| 2014-12-31 | $3.18 | $20.90 | x |
| 2015-12-31 | $1.99 | $20.90 | x |
| 2016-12-31 | $4.47 | $20.90 | x |
| 2017-12-31 | $2.73 | $20.90 | x |
| 2018-12-31 | $3.78 | $20.90 | x |
| 2019-12-31 | $4.75 | $20.90 | x |
| 2020-12-31 | $3.99 | $20.90 | x |
| 2021-12-31 | $3.37 | $20.90 | x |
| 2022-12-31 | $2.48 | $20.90 | x |
| 2023-12-31 | $2.64 | $20.90 | x |
| 2024-12-31 | $4.40 | $20.90 | x |
| 2025-12-31 | $7.16 | $20.90 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ACADIA Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 31.86%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 36.49%
- • Asset Turnover: 0.69x
- • Equity Multiplier: 1.27x
- Recent ROE (31.86%) is above the historical average (-52.74%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2000 | 0.00% | -236.41% | 0.13x | 0.00x | $-7.94 Million |
| 2001 | -80.65% | -387.88% | 0.17x | 1.23x | $-16.19 Million |
| 2002 | 0.00% | -205.05% | 0.39x | 0.00x | $-8.86 Million |
| 2003 | 0.00% | -191.00% | 0.23x | 0.00x | $-8.83 Million |
| 2004 | -84.47% | -562.89% | 0.11x | 1.32x | $-28.99 Million |
| 2005 | -86.70% | -311.56% | 0.18x | 1.59x | $-38.07 Million |
| 2006 | -67.08% | -553.89% | 0.09x | 1.33x | $-51.76 Million |
| 2007 | -49.49% | -746.39% | 0.06x | 1.18x | $-67.78 Million |
| 2008 | -121.23% | -4040.50% | 0.02x | 1.22x | $-69.54 Million |
| 2009 | -372.67% | -705.50% | 0.13x | 4.10x | $-46.36 Million |
| 2010 | 50.99% | 35.93% | 1.10x | 1.29x | $12.17 Million |
| 2011 | -97.44% | -1101.35% | 0.06x | 1.37x | $-25.10 Million |
| 2012 | -24.53% | -424.88% | 0.05x | 1.28x | $-29.35 Million |
| 2013 | -20.84% | -3314.24% | 0.01x | 1.04x | $-56.16 Million |
| 2014 | -29.88% | -77062.50% | 0.00x | 1.05x | $-123.42 Million |
| 2015 | -82.32% | -269578.69% | 0.00x | 1.11x | $-184.42 Million |
| 2016 | -52.35% | -1565.94% | 0.03x | 1.08x | $-323.23 Million |
| 2017 | -86.32% | -231.71% | 0.32x | 1.15x | $-322.93 Million |
| 2018 | -51.18% | -109.56% | 0.41x | 1.13x | $-293.10 Million |
| 2019 | -33.65% | -69.38% | 0.43x | 1.12x | $-305.17 Million |
| 2020 | -44.91% | -63.74% | 0.56x | 1.25x | $-344.28 Million |
| 2021 | -31.04% | -34.67% | 0.69x | 1.29x | $-221.96 Million |
| 2022 | -53.94% | -41.76% | 0.88x | 1.47x | $-256.02 Million |
| 2023 | -14.19% | -8.44% | 0.97x | 1.73x | $-104.46 Million |
| 2024 | 30.90% | 23.64% | 0.81x | 1.62x | $153.17 Million |
| 2025 | 31.86% | 36.49% | 0.69x | 1.27x | $268.26 Million |
Industry Comparison
This section compares ACADIA Pharmaceuticals Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ACADIA Pharmaceuticals Inc (ACAD) | $1.23 Billion | 0.00% | 0.27x | $2.65 Billion |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |